Updates are available Correction dated 2025-03-19
Click to view Correction: https://doi.org/10.1038/s41467-025-57496-0
-
Authors
Pierini, Stefano https://orcid.org/0000-0003-3082-1291
Gabbasov, Rashid
Oliveira-Nunes, Maria Cecilia https://orcid.org/0000-0002-4630-3918
Qureshi, Rehman
Worth, Alison https://orcid.org/0009-0008-8769-1129
Huang, Shuo
Nagar, Karan
Griffin, Crystal
Lian, Lurong
Yashiro-Ohtani, Yumi
Ross, Kayleigh
Sloas, Christopher
Ball, Michael
Schott, Benjamin https://orcid.org/0000-0003-4553-4068
Sonawane, Poonam
Cornell, Linara
Blumenthal, Daniel
Chhum, Sotheavy
Minutolo, Nicholas
Ciccaglione, Kerri
Shaw, Lauren
Zentner, Isaac
Levitsky, Hyam
Shestova, Olga
Gill, Saar https://orcid.org/0000-0001-7946-7778
Varghese, Bindu
Cushing, Daniel
Ceeraz DeLong, Sabrina
Abramson, Sascha
Condamine, Thomas https://orcid.org/0000-0001-9450-2762
Klichinsky, Michael https://orcid.org/0000-0001-8935-163X
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 23 December 2024
First Online: 15 January 2025
Change Date: 19 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-57496-0
Competing interests
: M.K. and S.G. are scientific co-founders of Carisma Therapeutics Inc, equity shareholders, and inventors of patents related to this work. S.P., R.G., M.C.O.-N., R.Q., A.W., S.H., K.N., C.G., L.L., Y.O., K.R., C.S., M.B., B.S., P.S., L.C., D.B., S.C., N.M., K.C., L.S., I.Z., D.C., S.C.D, S.A., T.C., and M.K. are employees of Carisma Therapeutics Inc and equity shareholders. H.L and S.G. are Scientific Advisory Board Members and shareholders of Carisma Therapeutics Inc. S.G. has patents related to CAR therapy with royalties paid from Novartis to the University of Pennsylvania. S.G. is a scientific co-founder and holds equity in Interius Biotherapeutics and Carisma Therapeutics Inc. S.G. is a scientific advisor to Carisma, Cartography, Currus, Interius, Kite, NKILT, Mission Bio, and Vor Bio. O.S. declares no competing interests. This work was funded by Carisma Therapeutics Inc which is pursuing the commercial development of related products.
